Pharmacologic inhibition of glycolysis prevents the development of lupus by altering the gut microbiome in mice

Ahmed S. Elshikha, Yong Ge, Josephine Brown, Nathalie Kanda, Mojgan Zadeh, Georges Abboud, Seung Chul Choi, Gregg Silverman, Timothy J. Garrett, William L. Clapp, Mansour Mohamadzadeh, Laurence Morel

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Gut dysbiosis has been associated with lupus pathogenesis, and fecal microbiota transfers (FMT) from lupus-prone mice shown to induce autoimmune activation into healthy mice. The immune cells of lupus patients exhibit an increased glucose metabolism and treatments with 2-deoxy-D-glucose (2DG), a glycolysis inhibitor, are therapeutic in lupus-prone mice. Here, we showed in two models of lupus with different etiologies that 2DG altered the composition of the fecal microbiome and associated metabolites. In both models, FMT from 2DG-treated mice protected lupus-prone mice of the same strain from the development of glomerulonephritis, reduced autoantibody production as well as the activation of CD4+ T cells and myeloid cells as compared to FMT from control mice. Thus, we demonstrated that the protective effect of glucose inhibition in lupus is transferable through the gut microbiota, directly linking alterations in immunometabolism to gut dysbiosis in the hosts.

Original languageEnglish (US)
Article number107122
JournaliScience
Volume26
Issue number7
DOIs
StatePublished - Jul 21 2023

Keywords

  • Immune system disorder
  • Microbiome
  • Pharmaceutical science

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Pharmacologic inhibition of glycolysis prevents the development of lupus by altering the gut microbiome in mice'. Together they form a unique fingerprint.

Cite this